Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Update

Kailera Therapeutics, Inc. (NASDAQ:KLRA) saw a large growth in short interest in April. As of April 30th, there was short interest totaling 1,954,558 shares, a growth of ∞ from the April 15th total of 0 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average daily volume of 1,694,308 shares, the short-interest ratio is currently 1.2 days.

Insiders Place Their Bets

In related news, Director Adam Koppel bought 1,562,500 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. This trade represents a 7.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Rtw Investments, Lp acquired 500,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the transaction, the insider directly owned 10,776,820 shares in the company, valued at approximately $172,429,120. This represents a 4.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Stock Performance

NASDAQ:KLRA traded down $0.46 on Friday, reaching $21.04. The stock had a trading volume of 482,218 shares, compared to its average volume of 796,741. Kailera Therapeutics has a 12-month low of $20.75 and a 12-month high of $28.23.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KLRA. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday. Evercore began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating on the stock. TD Cowen began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective on the stock. JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, William Blair began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.